Obiective: To assess the effect of transrectal radiofrequency
hyperthermia (TRFH) in 159 patients suffering from chronic
prostatitis (CP), and explore the changes of reactive oxygen
species in CP patients pre-treatment and post-treatment.
Methods: Patients diagnosed with chronic prostatitis were
randomized to 6 weeks of tamsulosin plus clarithromycin, TRFH
or TRFH with tamsulosin plus clarithromycin group,respectively.
The primary outcome measure was evaluated by the National
Institutes of Health Chronic Prostatitis Symptom Index.
Malondiadehyde (MDA), superoxide dismutase (SOD), and
nitrogen monoxide (NO) were measured by biochemical assay.
Zinc content was assayed by atomical spectrophotography.
Results: All 105 patients in the TRFH or TRFH with
tamsulosin plus clarithromycin group showed statistically
significant improvement of pain, QoL, and micturition domains
in comparison to the tamsulosin plus clarithromycin group, and
regardless of type IIIa or type IIIb CP, there was a significant
improvement in the TRFH or TRFH with tamsulosin plus
clarithromycin compared to tamsulosin plus clarithromycin
group (P<0.05). Compared with pre-treatment, MDA, NO and
zinc were decreased in type II and IIIa, while SOD were only
increased significantly in type II (P<0.05 ).
Conclusions: Our study reveal TRFH as a effective therapy
option for CP, especially type IIIa or type IIIb CP. The effects of
TRFH with tamsulosin plus clarithromycin group is superior to
the TRFH group or the tamsulosin plus clarithromycin group
alone. Comparison with pre-treatment, differences in ROS
levels in CP patients suggest that these factors could be used as
a biomarker to evaluate the symptoms of CP and the effects of